Exhibit 99.1 • Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024 • LockBody Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors ® "This is an exciting and pivotal time for Centessa," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "We are laser focused on executing the PRESent registrational studies for SerpinPC, a ...

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion.Second, a sector rotation may be ...

akinbostanciCentessa Pharmaceuticals (NASDAQ:CNTA) has become an interesting player in the biopharmaceutical field, characterized by an innovative business model and a unique portfolio. Unlike other companies, the unique structure of Centessa combines the flexibility of innovation of small-scale biotechs and the robust support of a large corporation that can give it an advantage in the turbulent world of drug development. Such a framework enables the company to concentrate on the development of its pipe ...

Financial Position - Centessa Pharmaceuticals has cash, cash equivalents, and short-term investments of $281.3 million as of September 30, 2023, expected to fund operations into 2026[406]. - As of September 30, 2023, the company had cash, cash equivalents, and short-term investments totaling $281.3 million[445]. - The company has filed a shelf registration statement covering the offering of up to $350.0 million in various securities, including ordinary shares and debt securities[449]. Revenue and Profitability - The company has not generated any revenue and relies on successful development and commercialization of product candidates for future profitability[408]. - The company expects to incur significant expenses and operating losses as it advances its clinical and preclinical programs[406]. - The company recorded a net loss of $38.6 million for the three months ended September 30, 2023, compared to a net loss of $53.9 million for the same period in 2022, reflecting a 28.4% improvement[422]. Research and Development - SerpinPC, a treatment for hemophilia, has shown favorable safety and efficacy in ongoing Phase 2a studies, with plans to present new data in December 2023[386][393]. - The registrational program for SerpinPC includes global studies, with the first subjects dosed in July and October 2023 for different hemophilia types[393]. - ORX750, an orally administered OX2 receptor agonist for narcolepsy, has demonstrated significant activity in preclinical models, with clinical development expected to begin in 2024[399]. - LB101, the first LockBody product candidate, is undergoing a Phase 1/2a study for advanced solid tumors, with the first subject dosed in March 2023[395]. - LB206, a second LockBody candidate for solid tumors, was announced in August 2023, showing promising preclinical data[389]. - The company has deprioritized several programs, including CBS001 and CBS004, while continuing to evaluate strategic partnerships for their development[405]. - The company expects to incur significant expenses related to ongoing development activities and anticipates a long-term increase in expenses as it continues research and development efforts[457]. Expenses - Research and development expenses for the three months ended September 30, 2023, were $28.2 million, a decrease of 23.2% from $36.7 million in the same period of 2022[433]. - Research and development expenses for the nine months ended September 30, 2023, totaled $94.7 million, a decrease of 25.6% from $127.2 million for the same period in 2022[437]. - The company incurred $13.0 million in research and development expenses for the SerpinPC program during the three months ended September 30, 2023, compared to $5.6 million in the same period of 2022, reflecting a 132.5% increase[426]. - General and administrative expenses for the three months ended September 30, 2023, were $12.0 million, slightly down from $12.3 million in the same period of 2022[428]. - General and administrative expenses for the nine months ended September 30, 2023, were $41.4 million, unchanged from the same period in 2022, with personnel expenses increasing by $2.6 million due to higher share-based compensation[440]. Income and Tax - Interest income increased to $3.0 million for the three months ended September 30, 2023, compared to $0.1 million in the same period of 2022[429]. - Interest income for the nine months ended September 30, 2023, was $7.5 million, up from $0.2 million in the same period of 2022, reflecting interest earned from cash and cash equivalents and short-term marketable securities[441]. - Interest expense for the three months ended September 30, 2023, was $2.5 million, an increase of 30.4% from $1.9 million in the same period of 2022[429]. - Interest expense increased to $7.3 million for the first nine months of 2023, up $2.3 million from the same period in 2022, due to a higher average interest rate on the Note Purchase Agreement[442]. - The company recorded an income tax benefit of $2.8 million for the three months ended September 30, 2023, compared to a benefit of $0.1 million in the same period of 2022[431]. - The income tax benefit for the nine months ended September 30, 2023, was $26.2 million, significantly higher than the $83 thousand benefit recorded in the same period of 2022[444]. Cash Flow - Net cash used in operating activities for the nine months ended September 30, 2023, was $129.3 million, an improvement from $149.0 million in the same period of 2022[452]. - Net cash used in investing activities was $108.7 million for the nine months ended September 30, 2023, primarily due to investments in U.S. Treasury securities[454]. Company Classification - The company is classified as an emerging growth company under the JOBS Act, allowing it to delay the adoption of new accounting standards until they apply to private companies[480]. - The company will remain an emerging growth company until it reaches total annual gross revenues of $1.235 billion or more or meets other specified criteria[480]. Other - The company has provided a full valuation allowance for its U.K. deferred tax assets due to a history of cumulative net losses, while it released a previously recorded valuation allowance for its U.S. deferred tax assets in Q2 2023[478]. - As of September 30, 2023, the company reported no material contractual obligations or commitments beyond those disclosed in Note 6[479].

The Company's unaudited interim consolidated financial statements include the accounts of Centessa Pharmaceuticals plc, and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Emerging Growth Company and Smaller Reporting Company We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act ("JOBS Act") enacted in April 2012. For so long as we remain an emerging growth company, we are permitted and intend to rely on ce ...

Table of Contents (Exact name of registrant as specified in its charter) England and Wales 98-1612294 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98-1612294 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3rd Floor 1 Ashley Road Altrin ...

| --- | --- | --- | |-------------------------------------------------------|-------|-------| | | | | | | | | | Corporate Overview Asset-Centric. Patient-Centric. | | | | | | | | | | | Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recomme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wale ...

Financial Status and Pipeline Overview - Centessa Pharmaceuticals had $484.2 million in cash and cash equivalents as of June 30, 2022, providing a cash runway into 2026 to enable clinical proof of concept readouts across the portfolio[6, 9, 52] - The company is developing multiple potential blockbuster assets with clinical readouts anticipated over the next two years[6, 52] Lead Asset Programs - **SerpinPC (Hemophilia B):** - The estimated market size for Hemophilia B is over $2 billion[8, 13] - Phase 2a open label extension (OLE) data is expected in Q4 2022, and registrational studies for hemophilia B are expected to start in the second half of 2022[9, 16] - In a Phase 2a study, the highest dose cohort (1.2 mg/kg) showed a median ABR reduction of 88% for all bleeds (reduced from 36.0 to 4.4) and a 94% reduction for spontaneous joint bleeds (reduced from 21.1 to 2.2)[19] - **LB101 (Solid Tumors):** - The estimated market size for solid tumors is $10 billion[8] - An IND (Investigational New Drug) submission is planned for late 2022[9, 30] - In preclinical studies, LB101 at 17 mg/kg resulted in tumor regression in 14 out of 16 mice in a difficult-to-treat mouse model[34] - **MGX292 (Pulmonary Arterial Hypertension - PAH):** - The estimated global market size for PAH is over $6 billion[8, 39] - Preclinical data demonstrated dose-dependent reversal of established lung vascular pathology in a Sugen-hypoxia rat model[42] - **OX2R Agonists (Narcolepsy Type 1 - NT1):** - The estimated market size for narcolepsy is over $2 billion[8, 47] - Approximately 50% of narcolepsy patients have NT1[47]